Cancer Gene Therapy Market Size, Growth, Trends | Report 2022-2030
The global cancer gene therapy market size was evaluated at around USD 4.55 billion in 2024 and it is projected to hit around USD 26.80 billion by 2034, growing at a CAGR of 19.40% from 2025 to 2034.
The cancer gene therapy market has witnessed notable growth in recent years, driven by advancements in genetic engineering technologies and the increasing prevalence of various types of cancer worldwide. Gene therapy for cancer involves the modification or manipulation of genetic material within a patient’s cells to treat or prevent cancer. This can include replacing mutated genes with healthy copies, inactivating malfunctioning genes, or introducing new genes to help fight the disease. These therapies offer a targeted approach compared to traditional cancer treatments such as chemotherapy and radiation, reducing side effects and improving treatment outcomes.
The growth of the cancer gene therapy market is primarily fueled by the increasing incidence of cancer globally, coupled with a rising demand for more effective and targeted treatment solutions. Traditional cancer treatments often come with significant side effects and limited long-term efficacy, prompting the healthcare industry to explore gene therapy as a promising alternative. Innovations in genomics and biotechnology have enabled researchers to identify cancer-causing genetic mutations, paving the way for therapies that can correct or silence these faulty genes.
Another major growth driver is the expanding investment landscape in gene therapy research and development. Both public and private sectors are actively funding gene therapy startups and projects, leading to a robust pipeline of clinical trials and potential product approvals. Advancements in gene delivery technologies, such as viral and non-viral vectors, have also improved the safety and efficiency of these therapies.
One of the most prominent trends in the cancer gene therapy market is the rapid adoption of CRISPR and other gene-editing technologies, which are revolutionizing how genetic mutations linked to cancer are targeted and corrected. These tools allow for precise editing of DNA, offering the potential to directly modify or silence oncogenes. Another key trend is the integration of artificial intelligence and bioinformatics in the development of personalized cancer gene therapies, helping researchers predict therapeutic outcomes and optimize treatment protocols based on patient-specific genetic data.
Another emerging trend is the increasing focus on combination therapies, where gene therapy is used alongside immunotherapy, chemotherapy, or radiation to achieve synergistic effects. For instance, using gene therapy to enhance the immune system’s ability to recognize and destroy cancer cells has shown promising results in clinical trials. Furthermore, non-viral delivery methods, such as nanoparticles and lipid-based systems, are gaining traction as safer and more scalable alternatives to viral vectors.
Despite its promising potential, the cancer gene therapy market faces several significant challenges that could impede its widespread adoption. One of the primary hurdles is the complexity and high cost associated with developing and manufacturing gene therapies. These treatments often require highly specialized infrastructure, rigorous testing, and strict quality control, making them financially burdensome for companies and healthcare providers. In addition, the regulatory landscape for gene therapy is still evolving, with strict safety standards and lengthy approval processes that can delay the introduction of new therapies to the market.
Another major challenge lies in the delivery of gene therapies to target cells within the body. Effective and safe delivery remains a critical barrier, particularly in solid tumors where reaching cancer cells deep within tissues is difficult. While viral vectors are commonly used, they can pose risks such as immune reactions or insertional mutagenesis. Non-viral vectors, though safer, often lack the same level of efficiency. Moreover, there are ethical concerns and public apprehension related to genetic manipulation, which can hinder patient acceptance and regulatory support.
North America accounted for the highest market share, reaching 65% in 2024. This dominance is largely attributed to the region’s advanced healthcare infrastructure, high levels of investment in biomedical research, and early adoption of innovative treatment technologies. The United States plays a central role in driving growth, supported by favorable regulatory pathways, substantial public and private sector funding, and the presence of key industry players. The region also hosts a large number of clinical trials for cancer gene therapies, particularly in the field of CAR-T cell therapy and CRISPR-based treatments, which further accelerates the commercialization of these technologies.
In the Asia Pacific region, the cancer gene therapy market is experiencing rapid growth due to the rising incidence of cancer, increasing healthcare expenditures, and significant advancements in biotechnology. Countries such as China, Japan, and South Korea are investing heavily in gene therapy research and development, with government initiatives aimed at supporting innovation in genomics and cell therapy. The presence of a large patient population and expanding biopharmaceutical manufacturing capabilities also contribute to the region’s market potential.
The large B-cell lymphoma segment led the market, capturing the highest revenue share of 54% in 2024.The development of CAR-T cell therapies, which have shown promising results in treating relapsed or refractory B-cell lymphomas, has significantly driven growth within this segment. Regulatory approvals for gene therapies targeting B-cell malignancies, such as axicabtagene ciloleucel and tisagenlecleucel, have also contributed to market expansion, as these therapies offer new hope to patients with limited treatment options.
The others segment is projected to witness the highest compound annual growth rate of 21.28% throughout the forecast period. These segments are also experiencing growth as research progresses in identifying genetic mutations and pathways associated with different cancer types. Innovative delivery technologies and increasing investment in oncology research are accelerating the development of gene-based therapies for these indications.
The lentivirus segment led the market, capturing the highest revenue share of 48% in 2024. Lentiviral vectors are derived from the human immunodeficiency virus (HIV) and are widely used in gene therapy research and clinical applications for various cancers, including hematologic malignancies and solid tumors. Their ability to infect both dividing and non-dividing cells offers a major advantage over other vector types, making them particularly useful in targeting cancer cells.
The others category within the vector type segment includes a variety of non-viral and alternative viral vectors such as retroviruses (non-lentiviral), plasmid DNA, adeno-associated viruses (AAV), and herpes simplex viruses (HSV). These vectors are being explored for their unique properties in delivering therapeutic genes into cancer cells. Non-viral vectors, in particular, are gaining attention due to their lower immunogenicity and ease of production. Although they may currently have lower transfection efficiency compared to viral vectors, advancements in nanoparticle technology and electroporation methods are enhancing their potential in cancer gene therapy.
The intravenous segment held the leading position in the market, accounting for the highest revenue share. This approach is particularly effective for treating hematologic malignancies and metastatic cancers, where the widespread circulation of therapeutic vectors is necessary. IV administration offers advantages such as precise dosage control and consistent bioavailability, which are crucial for achieving optimal therapeutic outcomes.
The AAV (adeno-associated virus) segment is projected to register the fastest CAGR of 45% during the forecast period. AAV vectors are frequently administered via systemic routes like intravenous infusion, but they are also adaptable to local delivery depending on the target tissue. Their ability to infect both dividing and non-dividing cells with low immunogenicity makes them suitable for in vivo gene transfer. In cancer gene therapy, AAVs are being explored for targeted delivery to tumors, often requiring precise administration techniques to maximize efficacy and minimize off-target effects.
By Indication
By Route of Administration
By Vector Type
By Regional
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Indication Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Gene Therapy Market
5.1. COVID-19 Landscape: Cancer Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Gene Therapy Market, By Indication
8.1. Cancer Gene Therapy Market, by Indication
8.1.1 Large B-Cell Lymphoma
8.1.1.1. Market Revenue and Forecast
8.1.2. Multiple Myeloma
8.1.2.1. Market Revenue and Forecast
8.1.3. Acute Lymphoblastic Leukemia (ALL)
8.1.3.1. Market Revenue and Forecast
8.1.4. Melanoma (lesions)
8.1.4.1. Market Revenue and Forecast
8.1.5. Others
8.1.5.1. Market Revenue and Forecast
Chapter 9. Global Cancer Gene Therapy Market, By Route of Administration
9.1. Cancer Gene Therapy Market, by Route of Administration
9.1.1. Intravenous
9.1.1.1. Market Revenue and Forecast
9.1.2. Others
9.1.2.1. Market Revenue and Forecast
Chapter 10. Global Cancer Gene Therapy Market, By Vector Type
10.1. Cancer Gene Therapy Market, by Vector Type
10.1.1. Lentivirus
10.1.1.1. Market Revenue and Forecast
10.1.2. RetroVirus & gamma RetroVirus
10.1.2.1. Market Revenue and Forecast
10.1.3. AAV
10.1.3.1. Market Revenue and Forecast
10.1.4. Modified Herpes Simplex Virus
10.1.4.1. Market Revenue and Forecast
10.1.5. Adenovirus
10.1.5.1. Market Revenue and Forecast
10.1.6. Others
10.1.6.1. Market Revenue and Forecast
Chapter 11. Global Cancer Gene Therapy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication
11.1.2. Market Revenue and Forecast, by Route of Administration
11.1.3. Market Revenue and Forecast, by Vector Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Indication
11.1.4.2. Market Revenue and Forecast, by Route of Administration
11.1.4.3. Market Revenue and Forecast, by Vector Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Indication
11.1.5.2. Market Revenue and Forecast, by Route of Administration
11.1.5.3. Market Revenue and Forecast, by Vector Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication
11.2.2. Market Revenue and Forecast, by Route of Administration
11.2.3. Market Revenue and Forecast, by Vector Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Indication
11.2.4.2. Market Revenue and Forecast, by Route of Administration
11.2.4.3. Market Revenue and Forecast, by Vector Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Indication
11.2.5.2. Market Revenue and Forecast, by Route of Administration
11.2.5.3. Market Revenue and Forecast, by Vector Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Indication
11.2.6.2. Market Revenue and Forecast, by Route of Administration
11.2.6.3. Market Revenue and Forecast, by Vector Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Indication
11.2.7.2. Market Revenue and Forecast, by Route of Administration
11.2.7.3. Market Revenue and Forecast, by Vector Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication
11.3.2. Market Revenue and Forecast, by Route of Administration
11.3.3. Market Revenue and Forecast, by Vector Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Indication
11.3.4.2. Market Revenue and Forecast, by Route of Administration
11.3.4.3. Market Revenue and Forecast, by Vector Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Indication
11.3.5.2. Market Revenue and Forecast, by Route of Administration
11.3.5.3. Market Revenue and Forecast, by Vector Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Indication
11.3.6.2. Market Revenue and Forecast, by Route of Administration
11.3.6.3. Market Revenue and Forecast, by Vector Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Indication
11.3.7.2. Market Revenue and Forecast, by Route of Administration
11.3.7.3. Market Revenue and Forecast, by Vector Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication
11.4.2. Market Revenue and Forecast, by Route of Administration
11.4.3. Market Revenue and Forecast, by Vector Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Indication
11.4.4.2. Market Revenue and Forecast, by Route of Administration
11.4.4.3. Market Revenue and Forecast, by Vector Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Indication
11.4.5.2. Market Revenue and Forecast, by Route of Administration
11.4.5.3. Market Revenue and Forecast, by Vector Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Indication
11.4.6.2. Market Revenue and Forecast, by Route of Administration
11.4.6.3. Market Revenue and Forecast, by Vector Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Indication
11.4.7.2. Market Revenue and Forecast, by Route of Administration
11.4.7.3. Market Revenue and Forecast, by Vector Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication
11.5.2. Market Revenue and Forecast, by Route of Administration
11.5.3. Market Revenue and Forecast, by Vector Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Indication
11.5.4.2. Market Revenue and Forecast, by Route of Administration
11.5.4.3. Market Revenue and Forecast, by Vector Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Indication
11.5.5.2. Market Revenue and Forecast, by Route of Administration
11.5.5.3. Market Revenue and Forecast, by Vector Type
Chapter 12. Company Profiles
12.1. Novartis AG.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol Myers Squibb (Juno Therapeutics).
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bluebird Bio, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Adaptimmune Therapeutics plc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Intellia Therapeutics, Inc..
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Intellia Therapeutics, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. CRISPR Therapeutics AG.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Poseida Therapeutics, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sorrento Therapeutics, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GenSight Biologics
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers